Efficacy of Prostaglandin E1 in the Ajuvant Treatment of Diabetic Nephropathy Patients and Its Inhibition on Inflammatory Factors / 中国药师

ABSTRACT

Objective:To study the efficacy of prostaglandin E1 in the patients with diabetic nephropathy and its inhibition on inflammatory factors. Methods:Totally 86 cases of diabetic nephropathy from June 2013 to June 2015 in our hospital were selected,and according to the random number,they were randomly divided into the observation group and the control group. The control group was treated with the conventional dietary restriction and therapy regimen including lowering blood pressure and blood sugar. The patients in the observation group were given prostaglandin E1 additionally. After the treatment,24h urine protein quantity,serum creatinine and blood urea nitrogen and the other basic indicators of renal function and the contents of sICAM-1 and hs-CRP were detected. Results:After the treatment,the contents of 24h urine protein,serum creatinine,blood urea nitrogen, sICAM-1 and hs-CRP in the two groups were notably decreased when compared with those before the treatment,and the decrease in the observation groups was more significant than that in the control group,and the difference was statistically significant(P <0. 05). During the course of treatment,no obvious adverse reactions appeared in the two groups. Conclusion:Prostaglandin E1 in the adjuvant treatment of diabetic nephropathy patients shows better therapeutic efficacy and inhibition on inflammatory factors with higher security,which should be promoted in clinics.